A recent Cochrane review has examined the effectiveness of medical marijuana for treating insomnia, revealing minimal benefits in sleep quality or total sleep time. Despite the widespread nature of insomnia, affecting one in three adults globally and approximately 10% suffering from chronic insomnia, researchers concluded that the current evidence is insufficient to draw definitive conclusions.
Read More
The review analyzed nine clinical trials involving 537 adults with insomnia. Findings indicated that medical marijuana did not provide significant improvements compared to placebo in sleep quality, duration, or daytime functioning. Additionally, the use of medical marijuana was associated with an increased risk of side effects such as dizziness and dry mouth.
Lead author Dr. Lucia Varela from the University of Manitoba stated that the evidence does not imply medical cannabis is ineffective but suggests that it lacks the robustness needed for firm conclusions. Senior author Luis Garegnani from University Hospital Italiano de Buenos Aires emphasized the limitations of the studies, noting they were generally small, short-term, and tested various cannabis products.
Both authors underscore the necessity for larger, long-term studies to better assess the effectiveness and safety of medical cannabis for insomnia treatment. They advise clinicians and patients to remain cautious and to consider personal factors in the absence of stronger evidence.